SFA
VRTX icon

Souders Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Souders Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.12M Buy
2,497
+491
+24% +$229K 0.13% 87
2025
Q4 		$909K Buy
2,006
+242
+14% +$104K 0.1% 94
2025
Q3 		$691K Buy
1,764
+455
+35% +$190K 0.08% 113
2025
Q2 		$583K Buy
1,309
+222
+20% +$102K 0.07% 124
2025
Q1 		$527K Sell
1,087
-60
-5% -$28K 0.07% 126
2024
Q4 		$462K Sell
1,147
-319
-22% -$148K 0.06% 129
2024
Q3 		$682K Buy
1,466
+30
+2% +$14.4K 0.1% 115
2024
Q2 		$673K Buy
1,436
+37
+3% +$16.1K 0.1% 112
2024
Q1 		$585K Buy
+1,399
New +$591K 0.09% 115

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Souders Financial Advisors's VRTX Position: Q1 2026 in Review

Souders Financial Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 24% in Q1 2026, buying an estimated $229K and bringing the position to 2,497 shares worth $1.12M. The position accounts for 0.13% of the portfolio, ranked #87.

Souders Financial Advisors first reported a position in VRTX in Q1 2024 and has held it in 9 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Souders Financial Advisors held 2,497 shares of Vertex Pharmaceuticals worth $1.12M as of Q1 2026.
  • Souders Financial Advisors bought 491 Vertex Pharmaceuticals shares in Q1 2026, an estimated $229K.
  • Vertex Pharmaceuticals made up 0.13% of Souders Financial Advisors's portfolio in Q1 2026, its #87 holding.
  • Souders Financial Advisors first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Souders Financial Advisors's 13F filing for Q1 2026, filed 4 May 2026.